Hemodialysis dose and long-term COVID-19 outcomes – a retrospective cohort study
DOI:
https://doi.org/10.15584/ejcem.2024.1.21Keywords:
dialysis dose, hemodialysis, hospitalization, long COVID, mortalityAbstract
Introduction and aim. Long-term outcomes of COVID-19 pose a global challenge, particularly impacting individuals with un derlying health conditions, including those who have undergone hemodialysis (HD). The study aimed to investigate the rela tionship between preexisting dialysis dose, measured by single pool Kt/V (spKt/V), and long-term outcomes of COVID-19 in patients undergoing HD.
Material and methods. Demographic, clinical, and laboratory parameters following COVID-19 recovery, and long-term out comes, including the presence of COVID-19 sequelae, hospitalization, and all-cause mortality during a year after COVID-19 were retrospectively analyzed.
Results. Out of the 195 patients included, there were 108 males (55.4%) and 87 females (44.6%), with a median age of 56 (44-63) years and a dialysis duration of 49 (31.3–85.2) months. Patients with spKt/V<1.4 had a significantly increased risk of long-term COVID-19 sequelae (HR 9.1, 95% CI: 3.4; 24.6), hospitalization (HR 7.6, 95% CI: 3.9; 14.6), and all-cause mortality (HR 8.5, 95% CI: 2.9; 25.8) within one year after COVID-19 recovery compared with those with spKt/V≥1.4. spKt/V cutoff point of ≤1.3 emerged as a significant risk factor for one-year hospitalization and mortality within our cohort.
Conclusion. Suboptimal dialysis dose, as indicated by spKt/V < 1.4, is associated with adverse long-term COVID-19 outcomes in patients undergoing HD. Optimizing dialysis adequacy may mitigate these risks. Further research is needed to validate these f indings and explore interventions to improve outcomes in this vulnerable population.
Supporting Agencies
This study was part of an ongoing project, “Exploring the Mechanisms of Development and Identifying Therapeutic Targets for Post-COVID Syndrome in Dialysis Patients” (National Study Registration Number 0122U000144), of the State Institution “Institute of Nephrology of the National Academy of Medical Science of Ukraine,” Kyiv, Ukraine.Downloads
References
Whitsel LP, Ajenikoko F, Chase PJ, et al. Public policy for healthy living: How COVID-19 has changed the landscape. Prog Cardiovasc Dis. 2023;76:49-56. doi: 10.1016/j.pcad.2023.01.002
Schiffl H, Lang SM. Long-term interplay between COVID-19 and chronic kidney disease. Int Urol Nephrol. 2023;55(8):1977-1984. doi: 10.1007/s11255-023-03528-x
Demiray A, Kanbay A, Kanbay M. Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely? Clin Kidney J. 2022;15(3):369-371. doi: 10.1093/ckj/sfab265
Stepanova N, Driianska V, Korol L, Snisar L, Savchenko S. Pre-existing serum indoxyl sulfate and COVID-19 outcomes in patients undergoing hemodialysis: A retrospective cohort study. Ukr J Nephrol Dial. 2023;2(78):61-68. doi: 10.31450/ukrjnd.2(78).2023.07
Miao J, Olson E, Houlihan S, Kattah A, Dillon J, Zoghby Z. Effects of SARS-CoV-2 vaccination on the severity of COVID-19 infection in patients on chronic dialysis. J Nephrol. 2023;36(5):1321-1328. doi: 10.1007/s40620-023-01617-9
Rysyev A, Poperechnyi I, Chernianu D, Filonov V, Pyankovskyi S, Khyzhuna A. COVID-19 clinical outcomes and risk factors in fully vaccinated hemodialysis patients: A single-center prospective cohort study. Ukr J Nephrol Dialys. 2022;4(76):43-50. doi: 10.31450/ukrjnd.4(76).2022.06
Reardon S. Long COVID risk falls only slightly after vaccination, huge study shows. Nature. 2022;10.1038/d41586-022-01453-0. doi: 10.1038/d41586-022-01453-0
Och A, Tylicki P, Polewska K, et al. Persistent post-covid-19 syndrome in hemodialyzed patients—a longitudinal cohort study from the North of Poland. J Clin Med. 2021;10(19):4451. doi: 10.3390/jcm10194451
Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of Long COVID symptoms. Front Med (Lausanne). 2023;10:1011936. doi: 10.3389/fmed.2023.1011936.
Fong SW, Goh YS, Torres-Ruesta A, et al. Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection. J Med Virol. 2023;95(5):e28774. doi: 10.1002/jmv.28774.
Alsahow A, Muenz D, Al-Ghonaim MA, et al. Kt/V: achievement, predictors and relationship to mortality in hemodialysis patients in the Gulf Cooperation Council countries: results from DOPPS (2012–18). Clin Kidney J. 2020;14(3):820-830. doi: 10.1093/ckj/sfz195
Churchill BM, Patri P. The Nitty-Gritties of Kt/Vurea Calculations in Hemodialysis and Peritoneal Dialysis. Indian J Nephrol. 2021;31(2):97-110. doi: 10.4103/ijn.IJN_245_19.
Rocco M, Daugirdas JT, Depner TA, et al. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis. 2015;66(5):884-930. doi: 10.1053/j.ajkd.2015.07.015
Silva RE, Santos EC, Justino PBI, et al. Cytokines and chemokines systemic levels are related to dialysis adequacy and creatinine clearance in patients with end-stage renal disease undergoing hemodialysis. Int Immunopharmacol. 2021;100:108154. doi: 10.1016/j.intimp.2021.108154
Ling XC, Kuo KL. Oxidative stress in chronic kidney disease. Ren Replace Ther. 2018;4:53. doi: 10.1186/s41100-018-0195-2
Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993;4(5):1205-1213. doi: 10.1681/ASN.V451205.
Santoro A. Confounding factors in the assessment of delivered hemodialysis dose. Kidney Int. 2000;76:19-27. doi: 10.1046/j.1523-1755.2000.07603.x
Lambie SH, Taal MW, Fluck RJ, McIntyre CW. Analysis of factors associated with variability in haemodialysis adequacy. Nephrol Dial Transplant. 2004;19(2):406-412. doi: 10.1093/ndt/gfg570
Aghsaeifard Z, Zendehdel A, Alizadeh R, Salehnasab A. Chronic hemodialysis: Evaluation of dialysis adequacy and mortality. Ann Med Surg (Lond). 2022;76:103541. doi: 10.1016/j.amsu.2022.103541
Valga F, Monzón T, Vega-Diaz N, Rodriguez-Perez JC, Ruiz-Santana S. Inflammation and hemodialysis adequacy: are C-reactive protein levels influenced by the dose of dialysis? Nefrología (Engl Ed). 2021;S0211-6995(21)00112-0. doi: 10.1016/j.nefro.2021.06.001
Kooman JP, Carioni P, Kovarova V, et al. Modifiable Risk Factors Are Important Predictors of COVID-19-Related Mortality in Patients on Hemodialysis. Front Nephrol. 2022;2:907959. doi: 10.3389/fneph.2022.907959
Altun E, Apaydın S. The relationship between dialysis adequacy and COVID-19 onset and mortality risk: Single center experience. Ann Clin Anal Med. 2023;14(2):157-161. doi: 10.4328/ACAM.21507.
Churchill BM, Patri P. The Nitty-Gritties of Kt/Vurea Calculations in Hemodialysis and Peritoneal Dialysis. Indian J Nephrol. 2021;31(2):97-110. doi: 10.4103/ijn.IJN_245_19
Vanholder R, Glorieux G, Eloot S. Once upon a time in dialysis: the last days of Kt/V? Kidney Int. 2015;88(3):460-465. doi: 10.1038/ki.2015.155
Maduell F, Ramos R, Varas J, et al. Hemodialysis patients receiving a greater Kt dose than recommended have reduced mortality and hospitalization risk. Kidney Int. 2016;90(6):1332-1341. doi: 10.1016/j.kint.2016.08.022
Lisowska KA, Pindel M, Pietruczuk K, et al. The influence of a single hemodialysis procedure on human T lymphocytes. Sci Rep. 2019;9(1):5041doi: 10.1038/s41598-019-41619-x
Lisowska KA, Storoniak H, Dębska-Ślizień A. T cell subpopulations and cytokine levels in hemodialysis patients. Hum Immunol. 2022;83(2):134-143. doi: 10.1016/j.humimm.2021.11.003
Angeletti A, Zappulo F, Donadei C, et al. Immunological Effects of a Single Hemodialysis Treatment. Medicina (Kaunas). 2020;56(2):71. doi: 10.3390/medicina56020071
González-Cuadrado C, Caro-Espada PJ, Chivite-Lacaba M, et al. Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients. Int J Mol Sci. 2023;24(2):1712. doi: 10.3390/ijms24021712
Cantarelli C, Angeletti A, Perin L, et al. Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. Clin Kidney J. 2022;15(10):1816-1828. doi: 10.1093/ckj/sfac174
Chen CY, Liu KT, Shih SR, et al. Adequacy of Hemodialysis Serves as an Independent Predictor of Humoral Response to ChAdOx1 Prime-Boost Vaccination in Hemodialysis Patients. Viruses. 2022;14(6):1149. doi: 10.3390/v14061149
Carriazo S, Mas-Fontao S, Seghers C, et al. Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study. Clin Kidney J. 2021;15(3):432-441. doi: 10.1093/ckj/sfab248.
Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(3):iii35-iii40. doi: 10.1093/ndt/gfy175
Prietl B, Odler B, Kirsch AH, et al. Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19. Front Immunol. 2022;13:821818. doi: 10.3389/fimmu.2022.821818
de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14(4):597-600. doi: 10.1016/j.dsx.2020.05.025
Yabuuchi N, Sagata M, Saigo C, et al. Indoxyl Sulfate as a Mediator Involved in Dysregulation of Pulmonary Aquaporin-5 in Acute Lung Injury Caused by Acute Kidney Injury. Int J Mol Sci. 2016;18(1):11. doi: 10.3390/ijms18010011.
Stepanova N, Drianska V, Rysyev A, Ostapenko T, Kalinina N. IL-6 and IL-17 as potential links between pre-existing hypertension and long-COVID sequelae in patients undergoing hemodialysis: A multicenter cross-sectional study. Research Square [preprint]. doi: 10.21203/rs.3.rs-2652671/v1
Chisavu L, Mihaescu A, Bob F, et al. Trends in mortality and comorbidities in hemodialysis patients between 2012 and 2017 in an East-European Country: a retrospective study. Int Urol Nephrol. 2023;55(10):2579-2587. doi: 10.1007/s11255-023-03549-6
Lee MJ, Park I, Kim H, Shin GT, Jeong JC. Preexisting comorbidities are associated with the mortality rate as well as the predialysis adverse events in incident dialysis patients. Kidney Res Clin Pract. 2021;40(3):419-431. doi: 10.23876/j.krcp.20.231
Demikhova N, Chernatska O, Mazur T, et al. Markers of cardiovascular complications in patients with type 2 diabetes mellitus and arterial hypertension. Bangladesh J Med Sc. 2018;17(2):319-322. doi: 10.3329/bjms.v17i2.35894.
Kooman JP, Van Der Sande FM. Body Fluids in End-Stage Renal Disease: Statics and Dynamics. Blood Purif. 2019;47(1-3):223-229. doi: 10.1159/000494583
Jhee JH, Hwang SD, Song JH, Lee SW. The Impact of Comorbidity Burden on The Association between Vascular Access Type and Clinical Outcomes among Elderly Patients Undergoing Hemodialysis. Sci Rep. 2019;9(1):18156. doi: 10.1038/s41598-019-54191-1
Sars B, Van Der Sande FM, Kooman JP. Intradialytic Hypotension: Mechanisms and Outcome. Blood Purif. 2020;49(1-2):158-167. doi: 10.1159/000503776
Sahathevan S, Khor BH, Ng HM, et al. Understanding Development of Malnutrition in Hemodialysis Patients: A Narrative Review. Nutrients. 2020;12(10):3147. doi: 10.3390/nu12103147
Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. 2023;29(2):334-343. doi: 10.1038/s41591-022-02156-9
Fitero A, Bungau SG, Tit DM, et al. Comorbidities, Associated Diseases, and Risk Assessment in COVID-19 - A Systematic Review. Int J Clin Pract. 2022;2022:1571826. doi: 10.1155/2022/1571826
Arjun MC, Singh AK, Pal D, et al. Characteristics and predictors of Long COVID among diagnosed cases of COVID-19. PLoS One. 2022;17(12):e0278825. doi: 10.1371/journal.pone.0278825
Notarte KI, de Oliveira MHS, Peligro PJ, et al. Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(24):7314. doi: 10.3390/jcm11247314
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
